VBI Vaccines Inc. (VBIV) Bundle
A Brief History of VBI Vaccines Inc. (VBIV)
Founding and Early Development
VBI Vaccines Inc. was founded in 2010 in Vancouver, Canada. The company was established with the focus on developing innovative vaccines to address unmet medical needs, particularly in infectious diseases and cancer.
Initial Public Offering
In 2015, VBI Vaccines went public, trading under the ticker symbol VBIV on the NASDAQ. The initial public offering priced at $5.00 per share, raising approximately $27 million to advance its vaccine development initiatives.
Acquisition of Targets and Technology
In March 2017, VBI acquired SciVac Therapeutics, a company specialized in the development and manufacturing of vaccines. This acquisition included their lead product, Sci-B-Vac, which represents a novel hepatitis B vaccine. The transaction amounted to approximately $12 million.
Clinical Trial Progress
VBI conducted several significant clinical trials in the years following its founding. In 2018, the company reported positive Phase 2 data for Sci-B-Vac, showing a superior immune response compared to the currently available hepatitis B vaccines.
Financial Performance
As of 2020, VBI reported total revenue of $1.2 million, a notable increase from $0.8 million in 2019. The company's net loss for 2020 was approximately $26.3 million.
Recent Developments and Strategic Partnerships
In 2021, the company partnered with the National Institutes of Health (NIH) to develop a therapeutic vaccine for COVID-19. The collaboration was aimed at leveraging VBI's enveloped virus-like particle (eVLP) platform technology.
Stock Market Performance
As of October 2023, VBIV's stock price has experienced fluctuations, with a 52-week range of $0.90 to $3.00. The company had a market capitalization of approximately $130 million.
Pipeline Overview
VBI's pipeline includes several candidates:
| Vaccine Candidate | Indication | Status | Estimated Timeline |
|---|---|---|---|
| Sci-B-Vac | Hepatitis B | Approved in Canada | 2020 |
| VBI-1901 | Glioblastoma | Phase 2 | Ongoing |
| COVID-19 Vaccine | COVID-19 | Preclinical | 2023 |
Funding and Investment
In 2022, VBI raised approximately $15 million through a private placement to fund the continued development of its vaccine candidates. The funding attracted interest from multiple institutional investors.
Regulatory Approvals
VBI successfully obtained regulatory approval for Sci-B-Vac from Health Canada in December 2020, with additional approvals sought in international markets.
Future Outlook
Looking ahead, VBI aims to expand its product offerings and pursue partnerships with larger pharmaceutical companies to enhance its market presence and financial stability.
A Who Owns VBI Vaccines Inc. (VBIV)
Shareholder Composition
Shareholder Composition
As of the latest available data, the ownership structure of VBI Vaccines Inc. consists of institutional investors, retail investors, and insiders. The following table outlines the major shareholders and their respective ownership percentages:
| Shareholder Type | Shareholder Name | Ownership Percentage (%) | Number of Shares Held |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 12.5 | 7,500,000 |
| Institutional Investor | Balyasny Asset Management | 7.8 | 4,680,000 |
| Retail Investor | Various | 20.2 | 12,120,000 |
| Insider | Jeffrey M. Baxter | 5.3 | 3,180,000 |
| Insider | Francis A. O'Dowd | 3.1 | 1,860,000 |
| Institutional Investor | Vanguard Group, Inc. | 9.6 | 5,760,000 |
Recent Financial Performance
VBI Vaccines Inc. reported financial results for the fiscal year ending December 31, 2022. The following are key financial metrics:
| Metric | Amount |
|---|---|
| Total Revenue | $8.5 million |
| Net Loss | ($22.3 million) |
| Cash and Cash Equivalents | $35.0 million |
| Total Assets | $45.0 million |
| Total Liabilities | $10.0 million |
Insider Transactions
The following table highlights significant insider transactions within VBI Vaccines Inc. during the past year:
| Date | Insider | Transaction Type | Shares Traded | Price per Share |
|---|---|---|---|---|
| March 15, 2023 | Jeffrey M. Baxter | Purchase | 150,000 | $2.10 |
| April 20, 2023 | Francis A. O'Dowd | Sale | 100,000 | $2.50 |
| July 10, 2023 | Jeffrey M. Baxter | Purchase | 75,000 | $1.80 |
Market Capitalization
The market capitalization of VBI Vaccines Inc. was approximately $90 million as of the end of September 2023, based on a stock price of $1.80 per share, with a total of 50 million shares outstanding.
Future Directions
VBI Vaccines Inc. is focusing on advancing its clinical pipeline, which includes the following programs:
- VBI-1901 (for glioblastoma)
- VBI-1501 (for hepatitis B)
- VBI-2901 (for COVID-19)
VBI Vaccines Inc. (VBIV) Mission Statement
Company Overview
VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing next-generation viral vaccines to help improve global health outcomes. The company employs its proprietary virus-like particle (VLP) technology to create vaccines that can prevent infectious diseases.
Mission Statement
VBI Vaccines' mission is to develop innovative vaccines for the prevention of infectious diseases, including hepatitis B and other viral infections, aiming to enhance the quality of life around the world.
Core Values
- Innovation: Commitment to scientific excellence and development of advanced vaccine technologies.
- Integrity: Adherence to ethical practices in research, development, and business operations.
- Collaboration: Building partnerships with global health organizations, academic institutions, and the pharmaceutical industry.
- Patient Focus: Prioritizing the needs of patients and communities in all efforts.
Current Product Pipeline
| Product Name | Indication | Development Stage | Expected Milestones | Target Market Size (USD) |
|---|---|---|---|---|
| VBI-2601 | Hepatitis B | Phase 2 Clinical Trials | Initiation of Phase 3 trials in 2024 | Approx. 3 billion |
| VBI-1901 | Glioblastoma | Phase 2 Clinical Trials | Data readout anticipated in late 2023 | Approx. 1 billion |
Financial Performance
As of Q2 2023, VBI Vaccines reported financial results indicating:
- Total Revenue: $3.1 million
- Net Income: -$7.5 million
- Cash and Cash Equivalents: $29.2 million
- Research and Development Expenses: $5.4 million
- General and Administrative Expenses: $3.7 million
Market Strategy
VBI Vaccines aims to leverage its unique VLP technology in various markets by:
- Strategic Partnerships: Collaborating with organizations like the National Institutes of Health (NIH).
- Global Reach: Targeting emerging markets with high unmet medical needs.
- Regulatory Engagement: Working closely with regulatory bodies to expedite product approvals.
Conclusion on Market Impact
With an increasing focus on vaccine development, VBI Vaccines is strategically positioned to tap into a market valued at over $60 billion globally for vaccines. This market is expected to grow due to rising infectious diseases and a greater emphasis on preventive healthcare.
How VBI Vaccines Inc. (VBIV) Works
Company Overview
VBI Vaccines Inc. (NASDAQ: VBIV) is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for infectious diseases and immuno-oncology utilizing its proprietary enveloped virus-like particle (eVLP) platform. As of October 2023, the company has a market capitalization of approximately $170 million.
eVLP Platform Technology
The eVLP platform technology is central to VBI's approach. This technology enables the presentation of viral antigens in a biologically relevant manner, which can stimulate a robust immune response. The platform's application can lead to vaccine candidates that are stable, non-infectious, and elicit both humoral and cellular immunity.
Current Pipeline
As of October 2023, VBI Vaccines has several key candidates in various stages of clinical development:
- VBI-1901: In Phase 2 clinical trials for glioblastoma.
- VBI-2601: In Phase 2 clinical trials for hepatitis B.
- VBX-102: Undergoing preclinical development targeting COVID-19.
| Vaccine Candidate | Indication | Phase | Expected Milestones |
|---|---|---|---|
| VBI-1901 | Glioblastoma | Phase 2 | Topline data in Q4 2023 |
| VBI-2601 | Hepatitis B | Phase 2 | Data readout in early 2024 |
| VBX-102 | COVID-19 | Preclinical | IND filing in 2024 |
Financial Overview
For the fiscal year ending December 31, 2022, VBI Vaccines reported total revenue of $2.5 million, primarily from collaboration agreements. The company ended the year with a cash balance of $58.8 million.
In its Q2 2023 financial results, VBI reported:
- Revenue: $1.2 million
- Net loss: $5.7 million
- Cash and cash equivalents: $49 million
Strategic Partnerships
VBI has established partnerships with various entities to advance its research. Notably, in 2022, VBI signed a collaboration agreement with the National Institutes of Health (NIH) to develop its hepatitis B vaccine, which enables access to advanced research and funding opportunities.
Market Landscape
The global vaccine market has been growing steadily, projected to reach $105 billion by 2025. With a robust pipeline, VBI is positioned to capture market share in specific therapeutic areas. The hepatitis B vaccine market alone is expected to reach $4.7 billion by 2026.
Research and Development
VBI Vaccines allocates a significant portion of its budget to R&D, totaling approximately $36 million in 2022. The company aims to enhance its pipeline and pursue novel vaccine candidates, leveraging its eVLP platform.
Conclusion on Performance Metrics
| Year | Total Revenue | Net Loss | Cash & Equivalents |
|---|---|---|---|
| 2021 | $3.1 million | $34 million | $82 million |
| 2022 | $2.5 million | $25 million | $58.8 million |
| 2023 (Q2) | $1.2 million | $5.7 million | $49 million |
Future Outlook
VBI is aiming to advance its clinical programs and expand its pipeline in the coming years, with a focus on addressing unmet medical needs in oncology and infectious diseases. The successful execution of its strategies will be pivotal in determining its future valuation and market position.
How VBI Vaccines Inc. (VBIV) Makes Money
Product Development
VBI Vaccines Inc. focuses on the development of innovative immunotherapies and vaccines, particularly in the fields of infectious diseases and immuno-oncology. Their most notable product candidates include:
- VBI-1901 - A therapeutic vaccine for glioblastoma multiforme.
- VBI-2601 - An envelope protein vaccine for the prevention of hepatitis B.
- VBI-1501 - A COVID-19 vaccine candidate.
Revenue Streams
The company generates revenue through various streams including:
- Grant funding from government and non-governmental organizations.
- Partnership agreements with larger pharmaceutical companies.
- Sales from developed products upon approval.
Financial Performance
As of the end of Q3 2023, VBI Vaccines reported financial results as follows:
| Metric | Q3 2022 | Q3 2023 |
|---|---|---|
| Total Revenue | $2.5 million | $3.1 million |
| Net Income (Loss) | $(10.2 million) | $(8.6 million) |
| Cash Position | $29.7 million | $25.2 million |
| Research and Development Expenses | $4.5 million | $4.0 million |
| General and Administrative Expenses | $2.7 million | $2.8 million |
Collaborations and Partnerships
VBI has established several collaborations to enhance its revenue potential:
- In 2021, VBI entered a partnership with the National Institutes of Health (NIH) for the development of their hepatitis B vaccine.
- Collaborations with major pharmaceutical companies for co-development and commercialization of products.
Market Opportunities
VBI is strategically positioned in growing markets such as:
- Hepatitis B market projected to reach $3.74 billion by 2027.
- Immuno-oncology market expected to exceed $110 billion by 2026.
Investment and Funding
The company has raised funds through various means, including:
- An equity offering in July 2023 raised approximately $15 million.
- Grant funding from the U.S. government totaling $2 million for the COVID-19 vaccine development.
Stock Performance
As of October 2023, VBI Vaccines' stock performance is summarized below:
| Metric | Value |
|---|---|
| Current Share Price | $0.68 |
| Market Capitalization | $123 million |
| 52-Week High | $1.20 |
| 52-Week Low | $0.45 |
Future Outlook
VBI's future financial prospects hinge on:
- Successful clinical trial outcomes for their product candidates.
- Expansion of partnerships and collaborations.
- Approval and commercialization of products leading to revenue generation.
VBI Vaccines Inc. (VBIV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support